30
May
Among the lasting echoes of AstraZeneca’s now-cooled M&A gamesmanship with Pfizer is a promise to grow sales a whopping 75% over 10 years, expecting to reach $45 billion by 2023. That sky-high estimate depends largely on the company’s pipeline cancer treatments, and this weekend’s meeting of the American Society of Clinical Oncology will shine a light on three drugs AstraZeneca projects to bring in about $12 billion at their peaks.
Source: Can AstraZeneca’s cancer pipeline come through on a $12B promise?
